Missed the Hims & Hers Rally? Clover Health Could Be Next

Core Viewpoint - Hims & Hers Health Inc. experienced significant stock volatility, reaching an all-time high of nearly $73 before dropping to$36, but there are reasons for investors to remain optimistic about the stock's long-term potential [1][2]. Group 1: Stock Performance - Hims & Hers stock rebounded by 24% from its recent lows, suggesting that the market may have found a bottom [3]. - Clover Health Investments Inc. is currently favored in the market, trading at 82% of its 52-week high, compared to Hims & Hers at only 62% [6]. - Clover's stock price is projected to reach a fair valuation of $5.0 per share, indicating a potential upside of 26$330.7 million in insurance revenue, a 9.1% increase year-over-year [8]. - Wall Street forecasts earnings per share (EPS) for Clover to improve significantly, with expectations of reaching $0.03 by Q2 2025, up from a current net loss of$0.02 per share [6][7]. Group 3: Investment Sentiment - The Vanguard Group increased its holdings in Clover stock by 2.0%, bringing their total position to $61.7 million, representing 3.9% ownership [12]. - Clover stock is currently trading at a price-to-book (P/B) ratio of 6.6x, which is above the industry average of 4.9x, indicating a premium valuation that some investors are willing to pay for perceived growth potential [12][13].